GSK to roll out five vaccines by 2010

07/1/2005 | Forbes · Wall Street Journal, The

GlaxoSmithKline plans to put five major vaccines on the market in the next five years and estimates global sales for all could reach $18 billion annually. GSK plans to launch the cervical cancer vaccine Cervarix; Rotarix for rotavirus gastroenteritis; Streptorix, for pneumococcal disease; an improved flu vaccine; and a combination vaccine for meningitis. A company official described the vaccine field as an area of "explosive growth," and noted improvements in biologics have allowed development of vaccines that previously failed.

View Full Article in:

Forbes · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI